RT Journal Article
SR Electronic
T1 Cellular immune response to SARS-CoV-2 infection in humans: a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20180679
DO 10.1101/2020.08.24.20180679
A1 Madhumita Shrotri
A1 May C. I. van Schalkwyk
A1 Nathan Post
A1 Danielle Eddy
A1 Catherine Huntley
A1 David Leeman
A1 Samuel Rigby
A1 Sarah V. Williams
A1 William H. Bermingham
A1 Paul Kellam
A1 John Maher
A1 Adrian M. Shields
A1 Gayatri Amirthalingam
A1 Sharon J. Peacock
A1 Sharif A. Ismail
YR 2020
UL http://medrxiv.org/content/early/2020/08/29/2020.08.24.20180679.abstract
AB Introduction Understanding the cellular immune response to SARS-CoV-2 is critical to vaccine development, epidemiological surveillance and control strategies. This systematic review critically evaluates and synthesises the relevant peer-reviewed and pre-print literature published in recent months.Methods For this systematic review, independent keyword-structured literature searches were carried out in MEDLINE, Embase and COVID-19 Primer for studies published from 01/01/2020-26/06/2020. Papers were independently screened by two researchers, with arbitration of disagreements by a third researcher. Data were independently extracted into a pre-designed Excel template and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised.Results 61 articles were included. Almost all studies used observational designs, were hospital-based, and the majority had important limitations. Symptomatic adult COVID-19 cases consistently show peripheral T cell lymphopenia, which positively correlates with increased disease severity, duration of RNA positivity, and non-survival; while asymptomatic and paediatric cases display preserved counts. People with severe or critical disease generally develop more robust, virus-specific T cell responses. T cell memory and effector function has been demonstrated against multiple viral epitopes, and, cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but the significance for protection and susceptibility, respectively, remains unclear.Interpretation A complex pattern of T cell response to SARS-CoV-2 infection has been demonstrated, but inferences regarding population level immunity are hampered by significant methodological limitations and heterogeneity between studies. In contrast to antibody responses, population-level surveillance of the cellular response is unlikely to be feasible in the near term. Focused evaluation in specific sub-groups, including vaccine recipients, should be prioritised.Competing Interest StatementJM is chief scientific officer, shareholder and scientific founder of Leucid Bio, a spinout company focused on development of cellular therapeutic agents. The authors report no other competing financial interests or conflicts of interest.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020192528 Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. MCIvS is funded by a NIHR Doctoral Fellowship (Ref NIHR300156). SAI is supported by a Wellcome Trust Clinical Research Training Fellowship (Ref No 215654/Z/19/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis was a systematic review based on analysis of openly published secondary data.ARDSAcute respiratory distress syndromeCOVID-19Coronavirus disease (2019)CRSCytokine release syndromeELISpotEnzyme-linked immune absorbent spot (assay)HCoVHuman Coronavirus (HKU1, 229E, OC43, NL63)IFN-γInterferon gammaMMembrane (protein)MEDLINEMedical Literature Analysis and Retrieval System OnlineMERSMiddle East Respiratory SyndromeMetaQATMeta Quality Appraisal ToolNPNucleocapsid proteinNSP7; NSP13Non-structural protein 7; non-structural protein 13PBMCPeripheral blood mononuclear cellsPCR; RT-PCRPolymerase chain reaction; reverse transcription polymerase chain reactionPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSARS-CoV-1Severe Acute Respiratory Syndrome Coronavirus-1SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2RBDReceptor binding domainRNARibonucleic acidTEMRAT effector memory cells re-expressing CD45RATFH; cTFHT follicular helper cells; circulating T follicular helper cellsThT helper cellsWHOWorld Health Organization